{"id":1386,"date":"2026-11-18T12:38:29","date_gmt":"2026-11-18T10:38:29","guid":{"rendered":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/"},"modified":"2026-11-18T12:38:37","modified_gmt":"2026-11-18T10:38:37","slug":"ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/","title":{"rendered":"eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>On 16 October 2026, the US Food and Drug Administration announced that CDER and CBER will accept eCTD v4.0 submissions to applications that were originally established in eCTD v3.2.2. This &#8220;forward compatibility&#8221; removes one of the main obstacles to moving an existing portfolio onto the new standard, and it arrives as the EU&#8217;s own eCTD v4.0 timeline firms up.<\/strong><\/p>\n\n<h2>What the FDA announced<\/h2>\n<p>The Federal Register notice (Docket FDA-2018-D-1216) states that FDA supports eCTD v4.0 submissions to applications that began life in v3.2.2, from 16 October 2026. In practical terms, a sponsor no longer needs to keep a product in v3.2.2 for the rest of its lifecycle simply because the original application was filed that way. Open regulatory activity and previously submitted content can continue while the sponsor moves to v4.0.<\/p>\n<p>Two points are worth stressing:<\/p>\n<ul>\n<li>The notice sets <strong>no mandatory date<\/strong> for eCTD v4.0 at FDA. It announces support, not a requirement.<\/li>\n<li>Submissions subject to section 745A(a) of the FD&amp;C Act must still use an eCTD version FDA currently supports, as listed in the FDA Data Standards Catalog.<\/li>\n<\/ul>\n\n<h2>Where the EU stands<\/h2>\n<p>EMA opened optional use of eCTD v4.0 for new centralised marketing authorisation applications in December 2025. According to the published EU roadmap, v4.0 becomes the strongly recommended format for new centralised applications from early 2027 and mandatory for new centralised applications from early 2028. Dates for products already in a v3.2.2 lifecycle, and for decentralised, mutual recognition and national procedures, are still to be communicated. Companies submitting to EOF through national, DCP or MRP routes should continue to plan in v3.2.2 until the EU network confirms otherwise.<\/p>\n\n<h2>Why v4.0 is more than a format change<\/h2>\n<ul>\n<li><strong>Context of use and document reuse:<\/strong> a document can be submitted once and referenced across sequences and applications.<\/li>\n<li><strong>Controlled vocabularies:<\/strong> structured metadata replaces much of the folder logic of v3.2.2.<\/li>\n<li><strong>Future CTD content:<\/strong> the revised quality structure in ICH M4Q(R2) is designed around v4.0, so the format will eventually decide how the quality dossier itself is organised.<\/li>\n<\/ul>\n\n<h2>Planning a transition<\/h2>\n<ul>\n<li>Confirm that your publishing tool and vendor support v4.0 for both FDA and EU regional modules<\/li>\n<li>Decide which products move first: new applications, or established US products now that forward compatibility exists<\/li>\n<li>Clean up document granularity and metadata before migration, not after<\/li>\n<li>Keep one eye on regional differences; FDA and EU timelines are not aligned<\/li>\n<\/ul>\n\n<h2>How PQRA helps<\/h2>\n<p>PQRA supports eCTD planning, publishing and lifecycle management for EU and national procedures, including EOF submissions, and helps companies assess eCTD v4.0 readiness across their portfolio.<\/p>\n<p><a href=\"\/el\/contact\/\">Talk to PQRA about your eCTD v4.0 readiness<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>On 16 October 2026, the US Food and Drug Administration announced that CDER and CBER will accept eCTD v4.0 submissions to applications that were originally established in eCTD v3.2.2. This &#8220;forward compatibility&#8221; removes one of the main obstacles to moving an existing portfolio onto the new standard, and it arrives as the EU&#8217;s own eCTD [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1387,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions - PQRA\" \/>\n<meta property=\"og:description\" content=\"On 16 October 2026, the US Food and Drug Administration announced that CDER and CBER will accept eCTD v4.0 submissions to applications that were originally established in eCTD v3.2.2. This &#8220;forward compatibility&#8221; removes one of the main obstacles to moving an existing portfolio onto the new standard, and it arrives as the EU&#8217;s own eCTD [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-18T10:38:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-18T10:38:37+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions\",\"datePublished\":\"2026-11-18T10:38:29+00:00\",\"dateModified\":\"2026-11-18T10:38:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/\"},\"wordCount\":445,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ectd4-forward-compatibility.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/\",\"name\":\"eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ectd4-forward-compatibility.png\",\"datePublished\":\"2026-11-18T10:38:29+00:00\",\"dateModified\":\"2026-11-18T10:38:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ectd4-forward-compatibility.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ectd4-forward-compatibility.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/","og_locale":"el_GR","og_type":"article","og_title":"eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions - PQRA","og_description":"On 16 October 2026, the US Food and Drug Administration announced that CDER and CBER will accept eCTD v4.0 submissions to applications that were originally established in eCTD v3.2.2. This &#8220;forward compatibility&#8221; removes one of the main obstacles to moving an existing portfolio onto the new standard, and it arrives as the EU&#8217;s own eCTD [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/","og_site_name":"PQRA","article_published_time":"2026-11-18T10:38:29+00:00","article_modified_time":"2026-11-18T10:38:37+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"2 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions","datePublished":"2026-11-18T10:38:29+00:00","dateModified":"2026-11-18T10:38:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/"},"wordCount":445,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ectd4-forward-compatibility.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/","url":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/","name":"eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ectd4-forward-compatibility.png","datePublished":"2026-11-18T10:38:29+00:00","dateModified":"2026-11-18T10:38:37+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ectd4-forward-compatibility.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ectd4-forward-compatibility.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/ectd-4-0-forward-compatibility-what-the-fdas-october-2026-notice-means-for-eu-and-us-submissions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"eCTD 4.0 Forward Compatibility: What the FDA\u2019s October 2026 Notice Means for EU and US Submissions"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=1386"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1386\/revisions"}],"predecessor-version":[{"id":1388,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1386\/revisions\/1388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/1387"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=1386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=1386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=1386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}